N-Phenaethyl-phthalamidsaeure | 19357-09-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Phenaethyl-phthalamidsaeure
• 英文别名: N-Phenethyl-phthalamic acid；2-(2-phenylethylcarbamoyl)benzoic acid
• CAS: 19357-09-6
• 化学式: C₁₆H₁₅NO₃
• mdl: MFCD00029938
• 分子量: 269.3
• InChiKey: XVQUUVCOFZFTDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-Phenaethyl-phthalamidsaeure 、 (RS)-α-ethynyl-3-phenoxybenzyl alcohol 生成 1-(3-phenoxyphenyl)prop-2-ynyl 2-(2-phenylethylcarbamoyl)benzoate
  参考文献：
  名称：

  HOLAN, G.;WALSER, R. A.

  摘要：

  DOI：
• 作为产物：
  描述：

  苯酐 、 2-苯乙胺 以 乙腈 为溶剂， 反应 10.0h， 以35%的产率得到N-Phenaethyl-phthalamidsaeure
  参考文献：
  名称：

  Rational Design of an Indolebutanoic Acid Derivative as a Novel Aldose Reductase Inhibitor Based on Docking and 3D QSAR Studies of Phenethylamine Derivatives

  摘要：

  A series of 45 phenethylamine derivatives were synthesized and evaluated for their inhibitory activity against pig kidney aldose reductase (ALR2, EC 1.1.1.21). Their IC50 values ranged from 400 muM to 24 muM. The binding modes of compounds at the active site of ALR2 were examined using flexible docking. The results indicated that phenethylamine derivatives nicely fit into the active pocket of ALR2 by forming various hydrogen bonding and hydrophobic interactions. 3D-QSAR analysis was also conducted using FlexX-docked alignment of the compounds. The best prediction was obtained by CoMSIA combined with hydrophobic and hydrogen bond donor/acceptor field (q(2) = 0.557, r(2) = 0.934). A new derivative, 4-oxo-4-(4-hydroxyindole)butanoic acid, was designed, taking into account the CoMSIA field and the binding mode derived by FlexX docking. This rationally designed compound exhibits an ALR2 inhibition with an IC50 value of 7.4 muM, which compares favorably to that of a well-known ALR2 inhibitor, tolrestat (IC50 = 16 muM) and represents a potency approximately 240-fold higher than that of an original phenethylamine lead compound, YUA001.

  DOI：

  10.1021/jm0205346

文献信息

• [EN] NOVEL CRYSTALLINE FORMS OF A BACE INHIBITOR, COMPOSITIONS, AND THEIR USE<br/>[FR] NOUVELLES FORMES CRISTALLINES D'UN INHIBITEUR DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2016025364A1

  公开（公告）日：2016-02-18

  The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.

  本发明提供了一种新颖的维鲁贝卡斯塔合成方法，以及两种新颖的维鲁贝卡斯塔的晶体形式，以及其药用可接受的组合物，这些组合物可能在治疗、预防、缓解和/或延迟Aβ病理和/或其症状的发生方面有用。本文披露了此类Aβ病理的非限制性示例，包括阿尔茨海默病。
• [EN] NOVEL CRYSTALLINE FORMS OF A BACE INHIBITOR, COMPOSITIONS, AND THEIR USE<br/>[FR] NOUVELLES FORMES CRISTALLINES D'UN INHIBITEUR DE BACE, COMPOSITIONS, ET UTILISATION ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016053767A1

  公开（公告）日：2016-04-07

  The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.

  本发明提供了维鲁贝卡斯塔特的四种晶体形式，以及其药学上可接受的组合物，每种形式可能用于治疗、预防、改善和/或延迟Aβ病理的发生和/或其症状。本文披露了这类Aβ病理的非限定示例，包括阿尔茨海默病。
• [EN] PROCESS FOR ENANTIOMERIC ENRICHMENT OF 2 ', 6 ' - PIPECOLOXYLIDIDE<br/>[FR] PROCÉDÉ D'ENRICHISSEMENT ÉNANTIOMERIQUE DE 2', 6'-PIPÉCOLOXYLIDIDE
  申请人：NEON LAB LTD

  公开号：WO2014009964A1

  公开（公告）日：2014-01-16

  The invention discloses a process for enantiomeric enrichment of 2',6'-pipecoloxylidide using a chiral carbamoyl benzoic acid to provide (S)-enantiomer in high yield and high enantiomeric purity. The invention also discloses novel intermediates formed in the process of enantiomeric enrichment of 2',6'-pipecoloxylidide, preparation of N- substituted amidic acids and alkylation of 2',6'-pipecoloxylidide.

  该发明揭示了一种利用手性碳酰苯甲酸对2',6'-哌啶甲醯氧乙酰胺进行对映体富集的过程，以高产率和高对映体纯度提供(S)-对映体。该发明还揭示了在对2',6'-哌啶甲醯氧乙酰胺进行对映体富集的过程中形成的新型中间体，N-取代酰胺酸的制备以及对2',6'-哌啶甲醯氧乙酰胺进行烷基化的方法。
• [EN] INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES<br/>[FR] INHIBITEURS DE PROTÉINES TYROSINE PHOSPHATASES
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2014055768A1

  公开（公告）日：2014-04-10

  Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.

  提供了从磷酸二氟甲基苯丙氨酸（F2Pmp）合成的新型蛋白酪氨酸磷酸酶（PTP）抑制剂化合物。还提供了使用这些化合物来抑制PTP酶（如PTP-MEG2），以及治疗与PTP不当活性相关的疾病、紊乱或病况（如2型糖尿病）的方法。
• [EN] PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CERTAINS COMPOSÉS DE CINNAMIDE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2010025197A1

  公开（公告）日：2010-03-04

  This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.

  这项发明涉及一种新的合成方法，中间体和前体，导致如下所示的化合物11和12的混合物。它还涉及对立体异构物混合物进行分离，以在实质上的立体化学纯度中提供化合物12。该发明的合成涉及制备如下所示的化合物7和化合物10，以及它们的反应以制备化合物11和化合物12的混合物。